Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]:
SEC Accession No. 0001193125-18-299225
Filing Date
2018-10-15
Accepted
2018-10-15 16:01:05
Documents
3
Effectiveness Date
2018-10-15

Document Format Files

Seq Description Document Type Size
1 POS EX d626148dposex.htm POS EX 32947
2 EX-5.1 d626148dex51.htm EX-5.1 6878
3 GRAPHIC g626148cooleyredlogo.jpg GRAPHIC 2644
  Complete submission text file 0001193125-18-299225.txt   44613
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: POS EX | Act: 33 | File No.: 333-227333 | Film No.: 181122281
SIC: 2836 Biological Products, (No Diagnostic Substances)